## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies**
- Source: Finviz | 20251223T103500 | Bullish | Relevance: 100%
- CRISPR Therapeutics stock saw a 3.7% increase following positive early data from studies on its zugocaptagene geleucel (zugo-cel) therapy candidate. This therapy is being evaluated for autoimmune diseases, showing deep B-cell depletion and meaningful clinical improvement, and for B-cell malignancies, where it demonstrated strong activity and a high complete response rate. The company also announced a collaboration with Eli Lilly to evaluate zugo-cel in combination with Jaypirca for aggressive B-cell lymphomas.

**2. CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112â„¢) in Autoimmune Diseases and Hematologic Malignancies**
- Source: GlobeNewswire | 20251222T131013 | Bullish | Relevance: 100%
- CRISPR Therapeutics announced encouraging preliminary data for zugocaptagene geleucel (zugo-cel) in autoimmune diseases, showing deep B-cell depletion and significant clinical improvement, including remission in a SLE patient. The company also reported positive single-agent activity in relapsed or refractory large B-cell lymphoma, with a high overall response rate. Additionally, a new Phase 1 basket trial for zugo-cel has been initiated in ITP and wAIHA, and a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas was established.

**3. CRISPR Therapeutics Provides Broad Update on Zugocaptagene**
- Source: GlobeNewswire | 20251222T083000 | Bullish | Relevance: 100%
- CRISPR Therapeutics provided an update on zugocaptagene geleucel (zugo-cel) for autoimmune diseases and hematologic malignancies, reporting encouraging preliminary data in autoimmune patients including sustained B-cell depletion and significant clinical improvement. The company also announced an overall response rate of 90% and a complete response rate of 70% in patients with relapsed or refractory large B-cell lymphoma. CRISPR Therapeutics initiated a new Phase 1 basket trial for zugo-cel in refractory primary immune thrombocytopenic purpura and warm autoimmune hemolytic anemia, and formed a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas.

**4. Is CRISPR Therapeutics Stock Yesterday's News?**
- Source: Finviz | 20251224T100955 | Neutral | Relevance: 100%
- CRISPR Therapeutics, once a high-flying stock due to the approval of its gene-editing therapy Casgevy, has seen its stock decline significantly from its 2021 peak. Despite the breakthrough technology, Casgevy's revenue generation has been slow due to the complexity of its rollout and the profit-sharing agreement with partner Vertex Pharmaceuticals. This has led some to question the company's immediate investment potential, suggesting it might be considered "yesterday's news" by some investors.

**5. CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer**
- Source: Sahm | 20251223T220956 | Bullish | Relevance: 100%
- CRISPR Therapeutics (NASDAQ: CRSP) has announced promising Phase 1 data for its investigational allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel), showing a 90% overall response rate and 70% complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL). The therapy also demonstrated encouraging results in autoimmune rheumatologic diseases with good tolerability and significant clinical improvement. The company plans to provide additional updates in the second half of 2026 and has partnered with Eli Lilly and Co. (NYSE: LLY) to evaluate zugo-cel in aggressive B-cell lymphomas.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Needham | $80 | $80 | 0% |
| 2025-12-23 | Citizens | $86 | $86 | 0% |
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Needham | reit | Buy |
| 2025-12-23 | Citizens | reit | Market Outperform |
| 2025-11-26 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (26.4%, 8.9 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.4B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 26.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 weakening modestly (-0.5% over 5 days). Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. RSI neutral at 51. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.44% (CS: 60) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 0.975x | Below |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $56.71
- **Stop Loss:** $50.73 (10.5% risk)
- **Target:** $62.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 200
- **Position Value:** $11,342.00
- **Portfolio %:** 11.34%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*